R&D News | pharmaphorum

News

Boehringer follows Sanofi with job cuts in France

Boehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more than 300 jobs, adding to several hundred losses at Sanofi last week.

News

AZ and CRUK team up to go all-in on CRISPR

AstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling and big data processing that will develop CRISPR technology to b

News

Moderna shares slide after record $604m US listing

RNA drug specialist Moderna smashed the record for an initial public offering (IPO) in the US on Friday, raising a whopping $604 million, although its shares retreated 19% after the debut.

News

Supernus says ADHD drug trounces rivals, but shares slide

Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the

News

After delayed IPO, Mereo gets US listing via OncoMed merger

UK biotech Mereo BioPharma is merging with Californian biotech OncoMed in an all-stock deal that swells its pipeline and gives it a potential licensing deal with Celgene.

News

Novartis takes Xolair follow-up into phase III hives trial

Novartis says it intends to move a drug for chronic spontaneous urticaria (CSU), a severe form of hives, into a phase III programme on the strength of a mid-stage study.

Boehringer follows Sanofi with job cuts in France

AZ and CRUK team up to go all-in on CRISPR

Moderna shares slide after record $604m US listing

Supernus says ADHD drug trounces rivals, but shares slide

After delayed IPO, Mereo gets US listing via OncoMed merger

Novartis takes Xolair follow-up into phase III hives trial

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks